{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for icosapent root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT04512066: Phase 2 Interventional Completed Schizophrenia, Schizoaffective Disorder
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03262792: Not Applicable Interventional Completed Knee Osteoarthritis
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02590952: Phase 1 Interventional Completed Solid Tumor
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03456349: Phase 1 Interventional Completed Alzheimer's Disease
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03013998: Phase 1/Phase 2 Interventional Recruiting Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03833700: Phase 1 Interventional Active, not recruiting Solid Neoplasms
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT01971515: Phase 1 Interventional Completed Solid Tumor
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT04250363: Phase 1 Interventional Completed Healthy
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
DDD107498 is a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. This molecule was developed
at the University of Dundee, UK by a research consortium. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. Preclinical development is underway in United Kingdom. As at July 2016, no recent reports of development had been identified for preclinical development in Malaria in United Kingdom.
Status:
Investigational
Source:
NCT03987074: Phase 2 Interventional Completed Nonalcoholic Steatohepatitis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03174977: Early Phase 1 Interventional Recruiting HIV-1-infection
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
